Ronald Richard sold $263k of EBS
director at Emergent BioSolutions Inc.. 21,984 shares at an average of $11.97, traded Dec 5, 2025, filed Dec 9, 2025.
Score components
- +15RoleDirector
- +13Trade size$263k at market
- +5Share of holdings soldSold 21% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001380177-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | SOpen-market sale Common Stock | -7,100 | $12.11 | $86k | 98,417 | Dec 9, 2025 |
| Dec 5, 2025 | MOption exercise Common Stock | +25,748 | $5.02 | $129k | 124,165 | Dec 9, 2025 |
| Dec 5, 2025 | FTax withholding Common Stock | -10,864 | $11.90 | $129k | 113,301 | Dec 9, 2025 |
| Dec 5, 2025 | SOpen-market sale Common Stock | -14,884 | $11.90 | $177k | 98,417 | Dec 9, 2025 |
| Dec 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -25,748 | $0.00 | $0 | 0 | Dec 9, 2025 |
Related signals
Other insiders at Emergent BioSolutions Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $126k 17,800 shares | -14% | |
| 3Weak | Emergent BioSolutions Inc. | Paul Anthony Williams SVP, Products Business | $20k 3,000 shares | -2% | |
| 20Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $188k 17,801 shares | -13% | |
| 12Weak | Emergent BioSolutions Inc. | Sujata Tyagi Dayal director | $86k 8,552 shares | -9% | |
| 14Weak | Emergent BioSolutions Inc. | Coleen Glessner EVP, Quality & Ethics, and CPL | $306k 30,608 shares | -17% | |
| 11Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $63k 7,086 shares | -9% | |
| 31Weak | Emergent BioSolutions Inc. | Donald W DeGolyer director | $68k 7,844 shares | -5% | |
| 2Weak | Emergent BioSolutions Inc. | Keith Katkin director | $49k 7,844 shares | -8% | |
| 54Moderate | EBSbuy Emergent BioSolutions Inc. | Joseph C Papa President and CEO | $350k 60,000 shares | +21% | |
| 35Weak | Emergent BioSolutions Inc. | Kathryn C Zoon director | $57k 10,000 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.